Fate Therapeutics
FATE
$4.78
Share price
-0.21%
Change (1 day)
-24.61%
Change (1 year)
Categories
P/S ratio for Fate Therapeutics (FATE)
P/S ratio as of April 2024 (TTM): 8.56
According to Fate Therapeutics 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 8.56063. At the end of 2023 the company had a P/S ratio of 5.80.
P/S ratio history for Fate Therapeutics from 2013 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 5.80 | -42.99% |
| 2022 | 10.2 | -89.82% |
| 2021 | 100 | -60.36% |
| 2020 | 252 | 81.87% |
| 2019 | 139 | -20.75% |
| 2018 | 175 | 123.55% |
| 2017 | 78.3 | 231.94% |
| 2016 | 23.6 | -40.72% |
| 2015 | 39.8 | |
| 2014 | N/A | -100% |
| 2013 | 132 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Becton Dickinson BDX | 3.47 | -59.51% | 🇺🇸 USA |
 Sarepta Therapeutics
SRPT | 8.83 | 3.13% | 🇺🇸 USA |
 PTC Therapeutics
PTCT | 2.12 | -75.22% | 🇺🇸 USA |
 Neurocrine Biosciences
NBIX | 7.12 | -16.78% | 🇺🇸 USA |
 Avidity Biosciences RNA | 201 | 2,253.41% | 🇺🇸 USA |